SOURCE: Good Start Genetics, Inc.

Good Start Genetics, Inc.

February 06, 2013 15:30 ET

Good Start Genetics to Present at 15th Annual BIO CEO & Investor Conference Monday, February 11th

CAMBRIDGE, MA--(Marketwire - Feb 6, 2013) - Good Start Genetics, ®Inc., an innovative molecular diagnostics company developing the new gold standard in carrier screening, announced today that it will present at the 2013 BIO CEO & Investor Conference at the Waldorf Astoria in New York, NY. Don Hardison, president and CEO of Good Start Genetics, is scheduled to present Monday, Feb. 11, at 2 p.m. EST.

Mr. Hardison will provide an overview of Good Start Genetics and its groundbreaking next-generation DNA sequencing based carrier screening service, as well as highlights from its first year on the market. Mr. Hardison will be available for one-on-one meetings with investors and media attending the conference.

Good Start Genetics also is proud to announce that four separate abstracts related to its technology have been accepted for presentation at the upcoming annual meetings of the Pacific Coast Reproductive Society (PCRS) and the American Congress of Medical Genetics and Genomics (ACMG).

Since its national launch in April 2012, Good Start Genetics' high-complexity, CLIA- and CAP-accredited laboratory has processed tens of thousands of test orders. The GoodStart Select™ next-generation gene sequencing technology detects common mutations in carriers across all 23 diseases recommended for testing by major medical societies as well as rare mutations that would go undetected by laboratories using older, traditional genotyping-based technologies. For example, most genotyping technologies detect about 100 mutations for cystic fibrosis (CF), while GoodStart Select™ detects 550 mutations.

BIO CEO & Investor Conference

Monday, Feb. 11th 

2:00 p.m. EST

Waldorf Astoria NY, Park South 
301 Park Ave New York, NY 10022

About Good Start Genetics, Inc.

Good Start Genetics is setting the new gold standard in carrier screening by making testing for the most comprehensive set of known and novel disease-causing mutations accessible for routine clinical practice. After years of development and rigorous validation, Good Start Genetics has harnessed the power of next-generation sequencing and other best-in-class technologies to provide highly accurate, actionable and affordable tests for all disorders recommended for genetic testing by ACOG and ACMG. For these reasons, fertility specialists and their patients can have a high degree of confidence in their carrier screening results, and no longer have to compromise accuracy for price. For more information, visit

About the BIO CEO & Investor Conference

The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. This year's conference will feature corporate presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside Chats with industry leaders, three Therapeutic Workshops and five Business Roundtables all drawing from seasoned industry executives and analysts. New this year, a special track of 25 high-caliber private companies will be presenting at the event, and plenary sessions will address timely business issues and industry trends. Attendees can expect many opportunities to schedule one-on-one meetings as well as numerous networking opportunities. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. Complimentary registration is available to qualified institutional (buy and sell-side), private equity, and venture investors and can be accessed here:

Contact Information